Compare SSM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSM | BOLT |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.3M |
| IPO Year | 2021 | 2021 |
| Metric | SSM | BOLT |
|---|---|---|
| Price | $2.55 | $3.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 25.6K | 22.0K |
| Earning Date | 05-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | $1,462,987.20 | N/A |
| Revenue Next Year | $48.49 | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $2.35 | $3.13 |
| 52 Week High | $10.54 | $7.20 |
| Indicator | SSM | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 29.42 | 43.28 |
| Support Level | N/A | $3.13 |
| Resistance Level | $4.43 | $4.35 |
| Average True Range (ATR) | 0.28 | 0.26 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 20.34 | 33.58 |
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and services include Complete Solar Solutions, Solar Charge Controllers, Solar Modules, Data Services, and Engineering Services. The company's single business segment manages the financing, research and development, and product commercialization.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.